Maravai LifeSciences Holdings Inc (NASDAQ: MRVI)’s stock price has decreased by -1.54 compared to its previous closing price of 5.19. However, the company has seen a 8.72% increase in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-11-09 that SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) — Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of November.

Is It Worth Investing in Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) Right Now?

Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) has a higher price-to-earnings ratio of 28.25x compared to its average ratio,, and the 36-month beta value for MRVI is at -0.27. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 1 rating it as “overweight,” 4 as “hold,” and 0 as “sell.”

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.

Sponsored

The average price suggested by analysts for MRVI is $9.11, which is $4.0 above the current market price. The public float for MRVI is 108.78M, and currently, shorts hold a 7.02% of that float. The average trading volume for MRVI on November 17, 2023 was 2.56M shares.

MRVI’s Market Performance

The stock of Maravai LifeSciences Holdings Inc (MRVI) has seen a 8.72% increase in the past week, with a -28.93% drop in the past month, and a -49.46% fall in the past quarter. The volatility ratio for the week is 7.46%, and the volatility levels for the past 30 days are at 7.09% for MRVI. The simple moving average for the past 20 days is -17.47% for MRVI’s stock, with a -57.02% simple moving average for the past 200 days.

MRVI Trading at -37.29% from the 50-Day Moving Average

After a stumble in the market that brought MRVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.76% of loss for the given period.

Volatility was left at 7.09%, however, over the last 30 days, the volatility rate increased by 7.46%, as shares sank -26.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -53.92% lower at present.

During the last 5 trading sessions, MRVI rose by +8.72%, which changed the moving average for the period of 200-days by -66.25% in comparison to the 20-day moving average, which settled at $6.10. In addition, Maravai LifeSciences Holdings Inc saw -64.29% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for MRVI

Current profitability levels for the company are sitting at:

The net margin for Maravai LifeSciences Holdings Inc stands at +24.94. The total capital return value is set at 46.51, while invested capital returns managed to touch 23.09. Equity return is now at value 4.80, with 1.09 for asset returns.

Based on Maravai LifeSciences Holdings Inc (MRVI), the company’s capital structure generated 97.89 points at debt to equity in total, while total debt to capital is 49.47. Total debt to assets is 23.38, with long-term debt to equity ratio resting at 95.74. Finally, the long-term debt to capital ratio is 48.38.

When we switch over and look at the enterprise to sales, we see a ratio of 1.40, with the company’s debt to enterprise value settled at 0.14. The receivables turnover for the company is 6.68 and the total asset turnover is 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.70.

Conclusion

In conclusion, Maravai LifeSciences Holdings Inc (MRVI) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.